Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113516 · ClinicalTrials.gov registry record · Phase 2
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00113516 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 84 participants.
The verdict
NCT00113516, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113516
The ClinicalTrials.gov registry entry for NCT00113516 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00113516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113516 about?
NCT00113516 is a clinical study titled "A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer". The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).
What is the current status of trial NCT00113516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2005-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00113516?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), sunitinib (DRUG).
Who is sponsoring clinical trial NCT00113516?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.